DMAC - CIK 0001401040
The table below shows DiaMedica Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.06M | -$22.08M | -$18.73M | -$11.51M | -$12.25M | -$9.19M |
| Capital expenditure | $40.00K | $25.00K | $24.00K | $81.00K | $22.00K | $47.00K |
| Investing cash flow | -$2.19M | $8.56M | -$18.30M | $11.54M | -$20.54M | -$16.13M |
| Dividends paid | - | - | - | - | - |
DiaMedica Therapeutics Inc. reported operating cash flow of -$29.06M for fiscal year 2025. That is down 31.6% from -$22.08M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$3.90M (FY 2017) to -$29.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $43.88M | $11.99M | $36.84M | -$6.00K | $30.09M | $28.84M |